Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display.

Journal Article

Chondroitin sulfate proteoglycan 4 (CSPG4) is a promising target for cancer immunotherapy due to its high level of expression in a number of malignant tumors, and its essential role in tumor growth and progression. Clinical application of CSPG4-targeting immunotherapies is hampered by the lack of fully human high-affinity CSPG4 antibodies or antibody fragments. To overcome this limitation, we performed affinity maturation on a novel human CSPG4 single-chain Fv fragment (scFv) using the random mutagenesis approach and screened for improved variants from a yeast display library using a modified whole-cell panning method followed by fluorescence-activated cell sorting. After six rounds of panning and sorting, the top seven mutant scFvs were isolated and their binding affinities were characterized by flow cytometry and surface plasmon resonance. These highly specific, affinity-matured variants displayed nanomolar to picomolar binding affinities to the CSPG4 antigen. While each of the mutants harbored only two to six amino acid substitutions, they represented ~270-3000-fold improvement in affinity compared to the parental clone. Our study has generated affinity-matured scFvs for the development of antibody-based clinical therapeutics targeting CSPG4-expressing tumors.

Full Text

Duke Authors

Cited Authors

  • Yu, X; Qu, L; Bigner, DD; Chandramohan, V

Published Date

  • September 2017

Published In

Volume / Issue

  • 30 / 9

Start / End Page

  • 639 - 647

PubMed ID

  • 28981720

Electronic International Standard Serial Number (EISSN)

  • 1741-0134

International Standard Serial Number (ISSN)

  • 1741-0126

Digital Object Identifier (DOI)

  • 10.1093/protein/gzx038

Language

  • eng